Charged Alpha Stock Encyclopedia

AstraZeneca (AZN) H1 2026 — AstraZeneca (AZN), the UK-based global pharma giant and world leader in oncology, reported H1 & Q2 2026 this morning (period ended June 30, 2026): first-half revenue rose 9% (+6% CER) to a record $30,672M and core EPS jumped 12% to $5.21, with core operating profit up 11%. Q2 accelerated — revenue +6% to $15,384M and core EPS +21% to $2.63 on margin expansion and a lower tax rate. Oncology led, up 18% to $14,124M (46% of revenue); Rare Disease rose 13% to ~$4.9B and Respiratory & Immunology ~9%, more than offsetting an 8% decline in CVRM from Farxiga's US loss of exclusivity and China volume-based procurement. Management RAISED the interim dividend to $1.06, logged ~30 approvals since Q4 2025, flagged 20+ high-value readouts in the next 18 months, and REAFFIRMED FY2026 guidance (revenue mid-to-high single-digit % CER, core EPS low-double-digit % CER, tax 18-22%) plus the $80B-by-2030 revenue ambition. Yet the ADR (~$169) sits near a 52-week low, ~20% below its $213 high. On an owner-earnings DCF — even leaning to the ambition path — our fair value lands near $160/ADR, modestly BELOW the price: a world-class franchise priced for a lot to go right. Our call: HOLD, 3/5. Wall Street rates it Buy (20 buy / 15 hold / 6 sell, 41 analysts; ~$187 avg target, +10%), so we're aligned on the business but a touch more cautious on value.

AstraZeneca (AZN) is Britain's biggest drugmaker and the world's leading oncology company, a ~$260B biopharma giant with one of the deepest late-stage pipelines in the industry. H1 2026 (reported July 27, 2026) was a clean beat-and-raise: revenue up 9% to a record $30.7B (+6% CER), core EPS up 12% to $5.21, and core operating profit up 11%; Q2 core EPS jumped 21% to $2.63. Oncology is now the engine — up 18% to $14.1B, 46% of revenue — with Rare Disease (+13%) and Respiratory & Immunology (+9%) outrunning an 8% decline in the heart-and-kidney (CVRM) unit from Farxiga's patent loss and China procurement. Management raised the interim dividend to $1.06, cited ~30 approvals since the last results, more than 20 high-value readouts over the next 18 months, and reaffirmed both FY2026 guidance and the ambition of $80B revenue by 2030. And yet the American shares (~$169) trade near a 52-week low, ~20% off the $213 high, on China, drug-pricing, and valuation worries. On our owner-earnings DCF — steady vs. $80B-ambition paths, blended and leaning optimistic — fair value lands near $160/ADR, a few percent BELOW the price. A wonderful company with almost no margin of safety today. Our call: HOLD, 3/5. We're aligned with Wall Street's view of the business (Buy: 20 buy / 15 hold / 6 sell, ~$187 avg target, ~+10%) but a touch more cautious on price. Own it for the quality; add on real weakness toward the low $140s. Watch the pipeline readouts and China every quarter. Not financial advice.

THE CALL: HOLD (3/5, A GREAT FRANCHISE AT A FULL PRICE — A BEAT-AND-RAISE BLUE CHIP WITH NO REAL MARGIN OF SAFETY) — base-case value ~$160 vs ~$169 today.

What to watch: the pipeline keeping its pace — more of the 20-plus high-value readouts hitting, oncology compounding, and visible progress toward the $80B-by-2030 revenue ambition — which would justify paying up and support an upgrade; the risk to respect is the opposite — a China (volume-based procurement) or US drug-pricing shock, or a run of pipeline failures like CARDIO-TTRansform, which at a premium ~18x forward multiple could re-rate the ADR lower

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

D.R. Horton (DHI) Q3 FY2026 — D.R. Horton (DHI), America's largest homebuilder by volume, reported fiscal Q3 2026 (quarter ended June 30, 2026): diluted EPS of $3.20 beat the ~$3.07 estimate but FELL 5% year-over-year, with net income down 12% to $904.9M on flat revenue of $9.2B. Homes closed rose 4% to 23,983 (high end of guidance), but home sales gross margin slipped to 20.7% (off the ~24% peak) as the company leaned on mortgage-rate buydowns and incentives. Net sales orders were flat at 23,084 homes ($8.4B) and the cancellation rate jumped to 20% from 17% — a demand-softening tell. The balance sheet stays a fortress: 23% debt-to-capital, $6.1B liquidity, book value/share up 5% to $84.85, and $742.8M returned in Q3 ($615.7M buybacks + $127.1M dividends), shrinking shares ~6%. Management trimmed FY26 revenue guidance to $32.5-33.0B (~84,000 homes) and reaffirmed ~$2.5B of buybacks. The stock (~$147) is down ~20% from its $185 high, near the 52-week low. At ~14x trailing earnings it looks cheap, but our mid-cycle DCF and ~1.6x-book cross-check land fair value near $135 — modestly below the price on earnings that are past their peak. Our call: HOLD, 3/5. The Street also rates it Hold (~$164 avg target), so we're aligned on the verdict, a shade more cautious on value.

D.R. Horton (DHI) is America's Builder — the largest US homebuilder by volume since 2002, roughly 85,000 homes a year across 126 markets in 36 states. Fiscal Q3 2026 (ended June 30, 2026) was a beat that isn't what it looks like: diluted EPS of $3.20 topped the ~$3.07 estimate but fell 5% YoY, net income dropped 12% to $904.9M, and revenue was flat at $9.2B. Homes closed rose 4% to 23,983 (high end of guidance) — but the company is buying that volume with price: home sales gross margin fell to 20.7% (from the mid-20s peak) on elevated incentives and mortgage-rate buydowns, and management expects incentives to stay elevated into Q4. The demand tell is under the hood: net sales orders were flat at 23,084 homes ($8.4B), and the cancellation rate jumped to 20% from 17%. The bright spot is capital allocation — a fortress balance sheet (23% debt/capital, $6.1B liquidity, book value/share +5% to $84.85), $742.8M returned in Q3 ($615.7M buybacks + $127.1M dividends), a fresh $0.45 dividend declared, and ~$2.5B of FY26 buybacks reaffirmed, shrinking the share count ~6%. Guidance was trimmed to $32.5-33.0B revenue and ~84,000 homes. The stock has slid ~20% from its $185 high to ~$147, near its 52-week low, and at ~14x trailing earnings looks cheap. But this is a cyclical past its earnings peak: running mid-cycle earnings and a normalized ~1.6x book, our fair value lands near $135 — modestly BELOW the price. A best-in-class builder with no margin of safety. Our call: HOLD, 3/5. We're aligned with the Street's Hold (~$164 avg target, 25 buys / 25 holds / 3 sells across 53 analysts), a shade more cautious on fair value. Own it for the quality and the buybacks; back up the truck only on real weakness toward the low $120s. Watch mortgage rates and the cancellation rate. Not financial advice.

THE CALL: HOLD (3/5, BEST-IN-CLASS BUILDER, LATE IN THE CYCLE — A BEAT ON FALLING EARNINGS WITH NO MARGIN OF SAFETY) — base-case value ~$135 vs ~$147 today.

What to watch: a durable drop in mortgage rates that revives demand, lets DHI dial back incentives, and re-expands home gross margins back toward the mid-20s — turning today's flat orders into growth and justifying an upgrade; the risk to respect is the opposite — rates higher-for-longer or a recession that hits jobs and confidence, pushing orders lower, incentives higher, and home gross margin below 20%, which would mean earnings have further to fall and the cheap-looking multiple only gets cheaper

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Honeywell (HON) Q2 2026 — Honeywell (HON) — now branded Honeywell Technologies and a pure-play automation company after spinning off Aerospace (HONA) on June 29, 2026 and Solstice Advanced Materials (SOLS) in late 2025 — reported a clean Q2 2026: adjusted EPS of $1.95 beat the ~$1.80 estimate (+10% YoY) on sales of $5.19B (+3% reported, +4% organic), segment margin expanded 100 bps to 19.0%, and orders jumped 16% to a ~$20B backlog. Management RAISED full-year 2026 guidance — adjusted EPS to $8.05–$8.35 (up 25–29%) and organic growth to 3–4%. Ignore the $16.65 GAAP EPS — it's a one-time gain from deconsolidating Quantinuum. The catch: at ~30x forward earnings with only mid-single-digit organic growth and ~$20B net debt, even our compounder-leaning owner-earnings DCF lands fair value near $205 — below the ~$243 price. Our call: HOLD, 3/5. We're more cautious than the Street's ~$257 target (Buy).

Honeywell just finished one of the most ambitious breakups in industrial history. Over the past year it spun off Advanced Materials as Solstice (SOLS) and then, on June 29, 2026, spun off Honeywell Aerospace as its own public company (HONA) — leaving what still trades as HON a focused, ~$77B pure-play automation company across Building Automation, Industrial Automation, and Process Automation & Technology. Q2 2026, the first quarter on the new standalone basis, was genuinely strong: adjusted EPS of $1.95 beat the ~$1.80 estimate (+10% YoY), sales rose 3% (4% organic) to $5.19B, segment margin expanded 100 bps to 19.0%, and orders jumped 16% to a ~$20B backlog — with Building Automation the crown jewel at a 27% margin and +9% organic. Management RAISED full-year guidance to adjusted EPS of $8.05–$8.35 (up 25–29%). One trap to avoid: the $16.65 GAAP EPS is a mirage from the one-time Quantinuum deconsolidation gain — the $1.95 adjusted figure is what counts. So the debate isn't quality — it's price. The stock has re-rated to ~30x forward earnings on the clean-compounder story, yet underlying organic growth is only 3–4%, two of three segments had soft spots (Process organic -1%, Industrial reported -5%), and ~$20B of net debt ($28.7B gross) sits on the balance sheet. Even leaning toward the optimistic compounder path at a quality discount rate, our owner-earnings DCF lands fair value near $205 — below today's ~$243. A wonderful business with no margin of safety. Our call: HOLD, 3/5. We're notably more cautious than the Street's ~$257 target (Buy, 19 of 29 analysts). Own it for the quality, add on real weakness toward $200, and watch organic growth and de-levering. Not financial advice.

THE CALL: HOLD (3/5, A GREAT BUSINESS AT A FULL PRICE — A CLEAN BEAT-AND-RAISE WITH NO MARGIN OF SAFETY) — base-case value ~$205 vs ~$243 today.

What to watch: hard evidence the compounder story is real — organic growth accelerating toward high-single-digits, Process returning to growth, segment margin pushing into the mid-20s%, and divestiture proceeds visibly cutting the ~$20B net debt — which would justify the ~30x multiple and prompt an upgrade; the risk to respect is the narrative cracking: organic growth stalling, margin expansion fading, or leverage capping buybacks, which at ~30x earnings could re-rate the stock hard

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

3M Company (MMM) Q2 2026 — 3M (MMM), the Post-it and Scotch-tape industrial icon, reported a clean Q2 2026 adjusted beat: adjusted EPS of $2.40 topped the ~$2.27 estimate (+11% YoY) on sales of $6.5B with adjusted organic growth of 5.4%, and adjusted operating margin rose 40 bps to 24.9%. GAAP was messier — EPS of $1.78 and a 15.1% operating margin (down 290 bps), weighed by a divestiture loss and litigation costs. Management RAISED full-year adjusted EPS guidance to $8.80–$8.95 (from $8.50–$8.70). The stock (~$173, up ~24% off its $139 low) sits near its $177 52-week high. The catch: even our turnaround-leaning DCF lands fair value near $158 — below the price, before fully charging the multi-year PFAS and earplug cash bill. Our call: HOLD.

3M is one of the great American industrial turnarounds in progress — the Post-it, Scotch-tape and respirator maker that spent years as a litigation punching bag (PFAS, Combat Arms earplugs, tens of billions in settlements) and is now, under new CEO William Brown, quietly running well again. Q2 2026 was a clean adjusted beat: adjusted EPS of $2.40 beat the ~$2.27 estimate (+11% YoY), sales of $6.5B grew 5.4% organically, and adjusted operating margin expanded 40 bps to 24.9%. GAAP told a rougher story — EPS of $1.78 and a 15.1% operating margin, down 290 bps, dragged by a divestiture loss and litigation. Safety & Industrial led with +8.2% organic growth and a 27.8% margin; Transportation & Electronics rose ~5.9%; only Consumer lagged (-1.8%). Management RAISED full-year adjusted EPS guidance to $8.80–$8.95 (from $8.50–$8.70), with adjusted FCF of $1.3B and $1.4B returned to shareholders. So the debate isn't quality — it's price. The stock has re-rated ~24% off its $139 low to ~$173, near its $177 high, at ~19x forward earnings. Even giving Brown full credit with a turnaround-compounder path AND a quality discount rate, our owner-earnings DCF lands fair value near $158 — below the price, and that already gives 3M credit before charging the real PFAS and earplug cash bill the adjusted numbers step around. A genuinely improving company with no margin of safety. Our call: HOLD, 3/5. We're a touch more cautious than the Street's split Buy (~$185 median target, +7%). Own it for the recovering quality, add on real weakness toward the mid-$150s, and watch reported free cash flow and the litigation runoff. Not financial advice.

THE CALL: HOLD (3/5, A REAL TURNAROUND, FULLY PRICED — A BEAT-AND-RAISE WITH NO MARGIN OF SAFETY) — base-case value ~$158 vs ~$173 today.

What to watch: durable evidence the turnaround is compounding — organic growth pushing past mid-single digits, reported (GAAP) free cash flow climbing as the PFAS and earplug settlement payments taper, and margins holding their gains — which would justify the re-rating and prompt an upgrade; the risk to respect is a fresh litigation escalation or a consumer/industrial slowdown, which at ~19x earnings with cash already bleeding to settlements could re-rate the stock hard

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Cleveland-Cliffs (CLF) Q2 2026 — Cleveland-Cliffs (CLF), the largest flat-rolled steelmaker in North America, delivered a genuine inflection quarter for Q2 2026: revenue of about $5.23B rose roughly 6% year over year, adjusted EBITDA roughly TRIPLED to about $286M — its highest in nearly two years — and free cash flow turned POSITIVE at about +$73M, the first positive FCF in two years, on steel shipments of about 4.0M net tons. It was still a GAAP loss (adjusted EPS about -$0.20, roughly in line), and the balance sheet still carries heavy debt, but the market loved the turn: the stock jumped about 17% to around $11.07 on the print. Management is now guiding toward about $3.3B in adjusted EBITDA and about $1.7B in free cash flow in 2027 — the debt-paydown bull case. Our call: HOLD. Not financial advice.

Cleveland-Cliffs is the largest flat-rolled steel producer in North America — a fully integrated iron-ore-to-finished-steel operator that supplies the automotive, infrastructure, and manufacturing end markets. Q2 2026 was a real inflection: revenue of about $5.23B was up roughly 6% year over year, adjusted EBITDA roughly TRIPLED to about $286M (its best in nearly two years), and free cash flow flipped POSITIVE at about +$73M — the first positive FCF in two years — on steel shipments near 4.0M net tons. The stock jumped about 17% to around $11.07 on the print. The catch: it's still GAAP-lossmaking (adjusted EPS about -$0.20, roughly in line with estimates) and still carries a heavy debt load, so the turn has to keep compounding. Management's 2027 targets — about $3.3B adjusted EBITDA and about $1.7B free cash flow — are the bull case and the debt-paydown driver. On a normalized-earnings-power plus mid-cycle EV/EBITDA frame, our base fair value lands near $10, a hair below the roughly $11.93 the stock trades at today, with a genuine add zone toward about $8 and below. Our call: HOLD, conviction 3/5 — a real operating inflection that the stock has already largely priced in. That puts us squarely ALIGNED with Wall Street, which is also at Hold across 44 analysts with an average target near $11.43 — just below the current price. Wait for a better entry. Not financial advice.

THE CALL: HOLD (3/5, A REAL INFLECTION THE STOCK ALREADY PRICED IN) — base-case value ~$10 vs ~$11.93 today.

What to watch: a durable move toward management's 2027 targets — about $3.3B adjusted EBITDA and about $1.7B free cash flow driving real debt paydown — plus a stronger steel-price and volume backdrop, which would push intrinsic value up toward the bull case and could justify an upgrade; the risks to respect are a cyclical rollover in steel prices and auto demand, the still-heavy debt load, and continued GAAP losses, any of which could re-rate a leveraged, capital-intensive cyclical quickly, which is why the add zone we want sits nearer $8 and below

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Cleveland-Cliffs (CLF) Q2 2026 — Cleveland-Cliffs (CLF), the largest flat-rolled steelmaker in North America, delivered a genuine inflection quarter for Q2 2026: revenue of about $5.23B rose roughly 6% year over year, adjusted EBITDA roughly TRIPLED to about $286M — its highest in nearly two years — and free cash flow turned POSITIVE at about +$73M, the first positive FCF in two years, on steel shipments of about 4.0M net tons. It was still a GAAP loss (adjusted EPS about -$0.20, roughly in line), and the balance sheet still carries heavy debt, but the market loved the turn: the stock jumped about 17% to around $11.07 on the print. Management is now guiding toward about $3.3B in adjusted EBITDA and about $1.7B in free cash flow in 2027 — the debt-paydown bull case. Our call: HOLD. Not financial advice.

Cleveland-Cliffs is the largest flat-rolled steel producer in North America — a fully integrated iron-ore-to-finished-steel operator that supplies the automotive, infrastructure, and manufacturing end markets. Q2 2026 was a real inflection: revenue of about $5.23B was up roughly 6% year over year, adjusted EBITDA roughly TRIPLED to about $286M (its best in nearly two years), and free cash flow flipped POSITIVE at about +$73M — the first positive FCF in two years — on steel shipments near 4.0M net tons. The stock jumped about 17% to around $11.07 on the print. The catch: it's still GAAP-lossmaking (adjusted EPS about -$0.20, roughly in line with estimates) and still carries a heavy debt load, so the turn has to keep compounding. Management's 2027 targets — about $3.3B adjusted EBITDA and about $1.7B free cash flow — are the bull case and the debt-paydown driver. On a normalized-earnings-power plus mid-cycle EV/EBITDA frame, our base fair value lands near $10, a hair below the roughly $11.93 the stock trades at today, with a genuine add zone toward about $8 and below. Our call: HOLD, conviction 3/5 — a real operating inflection that the stock has already largely priced in. That puts us squarely ALIGNED with Wall Street, which is also at Hold across 44 analysts with an average target near $11.43 — just below the current price. Wait for a better entry. Not financial advice.

THE CALL: HOLD (3/5, A REAL INFLECTION THE STOCK ALREADY PRICED IN) — base-case value ~$10 vs ~$11.93 today.

What to watch: a durable move toward management's 2027 targets — about $3.3B adjusted EBITDA and about $1.7B free cash flow driving real debt paydown — plus a stronger steel-price and volume backdrop, which would push intrinsic value up toward the bull case and could justify an upgrade; the risks to respect are a cyclical rollover in steel prices and auto demand, the still-heavy debt load, and continued GAAP losses, any of which could re-rate a leveraged, capital-intensive cyclical quickly, which is why the add zone we want sits nearer $8 and below

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Novocure (NVCR) Q2 2026 — Novocure (NVCR), the pioneer of Tumor Treating Fields cancer therapy (Optune), reported its strongest quarter ever for Q2 2026: record net revenue of $183.6M (+16% YoY) beat the ~$172M estimate, the net loss narrowed to -$0.13 (vs a -$0.33 estimate), gross margin expanded to 77.6%, and — for the first time in company history — adjusted EBITDA turned POSITIVE at +$10.8M. Global active patients hit a record 5,128 (+18%), led by Optune Gio in glioblastoma (4,636) with the growth kicker being Optune Pax in pancreatic cancer (285 US patients, 418 scripts, plus a new CE Mark) and Optune Lua in lung. Management RAISED full-year guidance to $710-725M in revenue (from $690-710M) and adjusted EBITDA to $0 to +$15M, and redesigned its LUNAR-2 trial to save ~$90M, redirected to pancreatic. The balance sheet holds ~$207M net cash. Yet the stock spiked 28% on the print, then round-tripped to ~$17.65 after an ~80% run off its $9.82 low — and the flagship TRIDENT glioblastoma trial showed no statistically significant survival benefit. Our call: SPEC BUY.

Novocure is the pioneer of Tumor Treating Fields (TTFields) — wearable Optune devices that use alternating electric fields to disrupt cancer cells as they divide, approved today in glioblastoma, pancreatic and lung cancer. Q2 2026 was the strongest quarter in company history: record net revenue of $183.6M (+16% YoY) beat the ~$172M estimate, the net loss narrowed to just -$0.13 a share (vs a -$0.33 estimate), gross margin expanded to 77.6%, and adjusted EBITDA turned POSITIVE at +$10.8M — the first profitable quarter, by that measure, ever. Record 5,128 active patients (+18%) span all three products, with Optune Pax in pancreatic cancer (285 US patients, 418 scripts, new CE Mark) the biggest swing factor. Management RAISED full-year guidance to $710-725M revenue and $0 to +$15M adjusted EBITDA, and cut ~$90M from a lower-return trial to fund pancreatic. Net cash sits near $207M, so the old dilution fear has faded. But the stock spiked 28% on the print and gave it all back to ~$17.65 (after an ~80% run off the $9.82 low), it's still GAAP-unprofitable (net loss $15.7M), and the flagship TRIDENT glioblastoma trial just missed on survival — a reminder this is a binary, single-technology bet. On a path-to-profitability + reverse-DCF frame, our base fair value lands near $23 (range ~$14 bear / ~$45 bull), implying ~30% upside. Our call: SPEC BUY, 3/5 — a genuine profitability inflection at a reasonable price, but speculative. We agree on direction with Wall Street's Buy (avg ~$26 target) but sit a notch more conservative. Own it small, add on the dips. Not financial advice.

THE CALL: SPEC BUY (3/5, A PROFITABILITY INFLECTION AT A REASONABLE PRICE — ASYMMETRIC BUT SPECULATIVE) — base-case value ~$23 vs ~$17.65 today.

What to watch: evidence the platform is truly scaling — Optune Pax and Optune Lua prescriptions compounding, a favorable Q4 2026 FDA decision in brain metastases, and adjusted EBITDA climbing well into positive territory — which would push the stock toward our ~$45 platform case and justify an upgrade; the risks to respect are another clinical trial miss (like TRIDENT), a stall in patient growth, or the margin turn reversing, any of which could re-rate a still-GAAP-unprofitable, single-technology small cap hard

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Teck Resources (TECK) Q2 2026 — Teck Resources (TECK), the Vancouver miner transforming from a coal-and-metals house into a focused copper producer, reported a record Q2 2026 (in C$, IFRS): adjusted EPS of C$1.93 crushed the ~C$1.41 estimate (a ~C$0.52 beat) on revenue of C$3.61B (+79% YoY). Adjusted EBITDA roughly tripled to ~C$2.2B — a record 61% margin — as copper production jumped 25% to 135,900 tonnes into record ~US$6.05/lb prices. Copper gross profit (pre-D&A) more than doubled to C$1.8B (from C$673M); zinc added C$353M. Operating cash flow was C$1.7B and the net cash position GREW C$756M in the quarter, with liquidity of C$10.3B including C$6.1B of cash. Strategically, Teck is advancing its merger of equals with Anglo American to create 'Anglo Teck,' a global copper champion, expected to close in 12-18 months with Chinese regulatory approval the key remaining step. The catch: the stock has run ~90% off its ~$31 low to ~$60 (US), near its ~$71 high, on record copper. Haircut US$6.05 copper toward mid-cycle, put a 5.5x EV/EBITDA on normalized ~C$6.5B EBITDA plus net cash, and fair value lands ~US$57 — roughly where it trades. Our call: HOLD, 3/5 — a world-class copper transformation, executed beautifully, but priced near fair value at peak prices with a big merger still to clear. Financials in C$; price/valuation in US$.

Teck Resources is a company in the middle of a dramatic makeover — from a sprawling coal-and-metals miner into a focused copper powerhouse, built on tier-one, long-life assets like the QB mine in Chile. Q2 2026 was a record quarter (reported in Canadian dollars): adjusted EPS of C$1.93 crushed the ~C$1.41 estimate on revenue up 79% to C$3.61B, and adjusted EBITDA roughly tripled to about C$2.2B — a record 61% margin. The driver was copper: production up 25% to 135,900 tonnes into record ~US$6.05/lb prices, with copper gross profit (pre-D&A) more than doubling to C$1.8B. The balance sheet is a genuine differentiator — net cash GREW by C$756M in the quarter, with C$10.3B of liquidity (C$6.1B cash) — a rarity in mining. And it's all happening while Teck advances a merger of equals with Anglo American to create 'Anglo Teck,' a global copper champion, targeted to close in 12-18 months (Chinese regulatory approval the last big hurdle). So the debate isn't quality — it's price and deal. The stock has run ~90% off its ~$31 low to ~$60 (US), near its ~$71 high, on record copper. We won't capitalize US$6.05 copper as if it lasts forever: on normalized ~C$6.5B EBITDA at 5.5x EV/EBITDA plus net cash, our fair value lands ~US$57 — roughly where it trades. Our call: HOLD, 3/5. A superbly-run copper transformation, but near fair value at peak commodity prices with a transformational merger still to clear. We're right in the Street's cautious zone — a soft, split Buy with US$ targets clustered in the mid-$50s to low-$60s (JP Morgan at Neutral). Own it for the assets, add on real weakness toward the low $50s. Not financial advice.

THE CALL: HOLD (3/5, A GREAT MINER, NEAR FAIR VALUE, AT PEAK COPPER — A RECORD QUARTER AND A MERGER, BUT LITTLE MARGIN OF SAFETY) — base-case value ~$57 vs ~$60.19 today.

What to watch: the Anglo American merger clearing Chinese regulatory approval and closing while copper prices stay firm, plus continued QB out-performance — which would re-rate TECK toward the higher multiple a global copper champion deserves and prompt a more bullish stance; the risk to respect is copper mean-reverting from record ~US$6.05/lb toward mid-cycle, or the merger being delayed or renegotiated, either of which strips the peak-cycle premium out of the stock

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

PG&E Corporation (PCG) Q2 2026 — PG&E (PCG), the largest investor-owned utility in America, reported a clean core beat for Q2 2026: non-GAAP core EPS of $0.40 topped the ~$0.36 estimate (+29% YoY) and GAAP EPS was $0.33 (+38% YoY), though revenue of $5.90B missed the ~$6.2B estimate. Management REAFFIRMED full-year core EPS guidance of $1.64-$1.66 (up ~10% at the midpoint) and repeated its plan for 9%+ annual EPS growth from 2027-2030, funded by a $73B capital plan through 2030 with NO additional equity — a ~10% rate-base CAGR. The catch is the balance sheet: ~$64.6B of debt against $33.9B of equity and roughly $3.2B/yr of interest, plus the ever-present California wildfire tail. That is exactly why PCG trades near 11x forward earnings — barely half the ~17-18x of regulated peers like DUK, SO, XEL and ED. Put a still-discounted 13x on next year's ~$1.80 of EPS and fair value lands near $22, about 23% above today's ~$18. Our call: BUY, 4/5 — a cheap, growing, self-funded regulated monopoly with a narrowing wildfire discount, in line with the Street's ~$23-24 Buy consensus. Respect the tail risk.

PG&E is the most controversial utility in America — the company whose equipment sparked the wildfires that pushed it into bankruptcy in 2019, wiping out shareholders. Today it is the largest investor-owned utility in the country, delivering power and gas to 16 million Californians, and it just posted a clean quarter: Q2 2026 non-GAAP core EPS of $0.40 beat the ~$0.36 estimate (+29% YoY), GAAP EPS was $0.33 (+38%), and management REAFFIRMED full-year core guidance of $1.64-$1.66. The one blemish was a revenue miss ($5.90B vs ~$6.2B) — but for a regulated utility much of revenue is pass-through cost; earnings, set by the regulator, are what matter. The growth engine is real: a $73B capital plan through 2030 grows the rate base ~10% a year and drives 9%+ annual EPS growth, and management says it needs NO new equity, so per-share growth isn't diluted away. So why does PCG trade at just ~11x forward earnings — barely half the ~17-18x of safe peers like Duke, Southern, Xcel and Consolidated Edison? Two reasons: ~$64.6B of debt (about $3.2B/yr in interest) and the ever-present California wildfire tail — the same risk that once zeroed the equity. The entire investment case is whether that ~40% discount narrows. Even a partial re-rating — a still-cheap 13x on next year's ~$1.80 of EPS — lands fair value near $22, about 23% above today's ~$18. Our call: BUY, 4/5 — a cheap, growing, funded, regulated monopoly with a slowly closing wildfire discount, aligned with the Street's ~$23-24 Buy consensus (18 buys, 11 holds, 1 sell). We stop at 4, not 5, out of respect for the wildfire tail — size it accordingly. Not financial advice.

THE CALL: BUY (4/5, A CHEAP UTILITY WITH A NARROWING WILDFIRE DISCOUNT — A FUNDED, REGULATED COMPOUNDER AT HALF THE PEER MULTIPLE) — base-case value ~$22 vs ~$17.85 today.

What to watch: evidence the wildfire discount is closing — clean fire seasons, constructive rate-case outcomes, the dividend climbing toward its 20%-by-2028 payout target, and any sign the market is granting a higher multiple — which would re-rate the stock toward peer valuations and prompt a more bullish stance; the risk to respect is a major new wildfire liability, an adverse legal or regulatory shock, or stress on the heavy ~$64.6B balance sheet, any of which would widen rather than close the discount

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

SkyWest, Inc. (SKYW) Q2 2026 — SkyWest (SKYW), the largest US regional airline, reported a rare Q2 2026 EPS MISS: diluted EPS of $2.54 came in below the ~$2.70 estimate and fell ~13% YoY (from $2.91), even as revenue rose ~7% to $1.10B. Net income was $101M vs $120M a year ago. The culprit was specific: aircraft fuel expense more than DOUBLED to $60.6M (from $27.5M) on higher per-gallon cost in the prorate business, plus a ~$9M other-income YoY swing. Yet the stock RALLIED ~8% (to ~$104) — because underneath, the operation improved: block hours +5% YoY / +9% sequential as parked jets reactivate (CRJ550 hrs +73%, CRJ900 +36%), pre-tax income +29% q/q, a funded E175 fleet build toward ~300 by end-2027, debt down to $2.3B, and a fresh +$250M buyback authorization (~$313M available). Our owner-earnings DCF (12% discount) lands fair value near $122 vs ~$104 — ~17% upside. Our call: BUY, 4/5.

SkyWest is the largest regional airline in America — the operator that flies the smaller jets you board under the United, Delta, American and Alaska brands, with ~500 aircraft to 240+ destinations. Q2 2026 was a rare miss on the headline: diluted EPS of $2.54 fell short of the ~$2.70 estimate and dropped ~13% YoY, even though revenue rose ~7% to $1.10B. The whole miss traces to two lines: aircraft fuel MORE THAN DOUBLED to $60.6M (from $27.5M) as per-gallon cost jumped in SkyWest's prorate flying (the slice where it, not the major, pays for fuel), plus a ~$9M one-time other-income comparison that didn't repeat. It was a cost-line miss, not a demand miss. Underneath, the business inflected: block hours rose 5% YoY and 9% sequentially as parked regional jets return to service (CRJ550 block hours +73%, CRJ900 +36%) on an easing pilot shortage, and pre-tax income jumped 29% from Q1. The fleet story is the bull case: a funded, largely pre-sold build to ~300 E175s by end-2027 (69 firm deliveries, +33 options, +50 purchase rights), each flying under a long fixed-fee contract. Capital allocation is aggressive and shareholder-friendly: $75M repurchased in Q2, $150M in H1, debt down to $2.3B, and the board just added +$250M to the buyback (~$313M available; no dividend). That's why the stock RALLIED ~8% to ~$104 on a miss. Even leaning conservative and using a demanding 12% discount rate for a leveraged, cyclical airline, our owner-earnings DCF lands fair value near $122 — about 17% above the price — and notably every Wall Street target ($108–$122, ~$115 avg) sits above the price too. The honest catch: the discount is structural (major-airline concentration, $2.3B of aircraft debt, cyclicality, no ticket pricing power), so this is a cheap operator turning a corner, not a franchise that re-rates to the sky. Our call: BUY, 4/5. We're a touch more bullish than the Street's Buy (10 buy / 7 hold; Goldman cut to Neutral this month). Own it for the value and the turn, add on weakness in the low $90s, and watch the partner contracts. Not financial advice.

THE CALL: BUY (4/5, A RARE MISS ON A CHEAP, IMPROVING REGIONAL BUYING BACK ITS STOCK — THE MISS WAS FUEL, NOT DEMAND) — base-case value ~$122 vs ~$104 today.

What to watch: prorate fuel costs normalizing, the new E175s entering revenue service on schedule, and block hours climbing as more parked jets return — a combination that would drive a clean earnings re-acceleration into 2027 and support a re-rating; the risks to respect are a major partner cutting or renegotiating flying, a travel recession, or trouble financing the aircraft order book, given the customer concentration and $2.3B of aircraft debt

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.